Bearish companies reappear in Grifols after 25% rise
The blood products company is again facing bearish pressure to extend a stock market rally that has reached 25% from lows recorded in January.
The truce of the bearish companies in Grifols gave way two days later to a double offensive. The power of growth accumulated by Ibex shares interest aroused again specialized hedge fundsare traded in short positions.
Grifols Class A shares They fell to the ground on January 19th.when they approached Capricorn in 8.36 euros41% lower than the day before the Got attack
The truce of the bearish companies in Grifols gave way two days later to a double offensive. The power of growth accumulated by Ibex shares interest aroused again specialized hedge fundsare traded in short positions.
Grifols Class A shares They fell to the ground on January 19th.when they approached Capricorn in 8.36 euros, which is 41% lower than the day before the attack on Gotham City. This has since sparked a stock market comeback, leading to six of seven days leftwith accumulated balance +25%.
Yesterday, this rebound was interrupted, falling 2.92%, which coincided with the double pressure it received again from bearish companies. Over the previous two days, Tuesday and Wednesday, the CNMV records changed. two hedge funds appeared with short positions exceeding 0.50% of Grifols’ capital in each case, this is the minimum percentage that forces companies to disclose their bearish exposure.
Qube Research and Technology revealed 0.50% Grifols capital in short positions. The hedge fund has so far stayed away from the blood products company, according to CNMV reports.
Yesterday another bearish signature, WorldQuantthere was also a significant participation in the capital of Ibex, in particular 0.51%. In this case, the hedge fund has already reported several participations in Grifols in 2023, with participation always very close to the 0.50% threshold. The last notice was dated July last year.
The renewed interest that Grifols has generated among bears in recent days has stalled the blood products company’s return to the stock market, to the point where intraday lows were recorded below level of ten euros per share.
To date, the company has accumulated adjustment about 35% in terms of year sum, the highest among Capricorn representatives.